Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment
Latest Information Update: 14 May 2025
At a glance
- Drugs AHB 137 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors AusperBio
Most Recent Events
- 07 May 2025 Interim results presented in an AusperBio Therapeutics media release.
- 07 May 2025 According to an AusperBio Therapeutics media release, data from this trial will be presented at the annual European Association for the Study of the Liver (EASL) Congress 2025, held May 7-10 in Amsterdam, the Netherlands.
- 23 Apr 2025 Planned primary completion date changed from 1 Apr 2025 to 2 Jun 2025.